<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7267115\results\search\disease\results.xml">
  <result pre="A.1NgSiew C.https://orcid.org/0000-0002-6850-44543RubinDavid T.https://orcid.org/0000-0001-5647-17234ChristensenBritthttps://orcid.org/0000-0002-8746-42751britt.christensen@mh.org.au[1], Department of GastroenterologyThe Royal Melbourne HospitalMelbourneVic.Australia[2], Victorian" exact="Infectious" post="Diseases UnitThe Royal Melbourne HospitalMelbourneVic.Australia[3], Department of Medicine and"/>
  <result pre="C.https://orcid.org/0000-0002-6850-44543RubinDavid T.https://orcid.org/0000-0001-5647-17234ChristensenBritthttps://orcid.org/0000-0002-8746-42751britt.christensen@mh.org.au[1], Department of GastroenterologyThe Royal Melbourne HospitalMelbourneVic.Australia[2], Victorian Infectious" exact="Diseases" post="UnitThe Royal Melbourne HospitalMelbourneVic.Australia[3], Department of Medicine and TherapeuticsInstitute"/>
  <result pre="ScienceThe Chinese University of Hong KongHong Kong Special Administrative RegionChina[4]," exact="Inflammatory" post="Bowel Disease CenterUniversity of Chicago MedicineChicagoILUSA *Correspondence Britt Christensen,"/>
  <result pre="University of Hong KongHong Kong Special Administrative RegionChina[4], Inflammatory Bowel" exact="Disease" post="CenterUniversity of Chicago MedicineChicagoILUSA *Correspondence Britt Christensen, The Royal"/>
  <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  <result pre="rapidly across the globe with no regard for borders. The" exact="primary" post="management of IBD involves treating uncontrolled inflammation with most"/>
  <result pre="regard for borders. The primary management of IBD involves treating" exact="uncontrolled" post="inflammation with most patients requiring immuneâ€�based therapies. However, these"/>
  <result pre="system and potentially place IBD patients at increased risk of" exact="infections" post="and infectious complications including those from COVIDâ€�19. Aim To"/>
  <result pre="potentially place IBD patients at increased risk of infections and" exact="infectious" post="complications including those from COVIDâ€�19. Aim To summarise the"/>
  <result pre="the COVIDâ€�19 pandemic, review unique concerns regarding IBD management and" exact="infection" post="risk during the pandemic and assess COVIDâ€�19 management options"/>
  <result pre="patients do not appear to be more susceptible to SARSâ€�CoVâ€�2" exact="infection" post="and there is no evidence of an association between"/>
  <result pre="of COVIDâ€�19. IBD medication adherence should be encouraged to prevent" exact="disease" post="flare but where possible highâ€�dose systemic corticosteroids should be"/>
  <result pre="be encouraged to prevent disease flare but where possible highâ€�dose" exact="systemic" post="corticosteroids should be avoided. Patients should exercise social distancing,"/>
  <result pre="patient develops COVIDâ€�19, immune suppressing medications should be withheld until" exact="infection" post="resolution and if trial medications for COVIDâ€�19 are being"/>
  <result pre="management presents a challenge in the current COVIDâ€�19 pandemic. The" exact="primary" post="focus should remain on keeping bowel inflammation controlled and"/>
  <result pre="current COVIDâ€�19 pandemic. The primary focus should remain on keeping" exact="bowel" post="inflammation controlled and encouraging medication adherence. fig-count: table-count: page-count:"/>
  <result pre="central Hubei Province, China.1, 2, 3 The virus causes the" exact="disease" post="COVIDâ€�19, which manifests as a severe acute respiratory illness"/>
  <result pre="virus causes the disease COVIDâ€�19, which manifests as a severe" exact="acute" post="respiratory illness that can be complicated by acute respiratory"/>
  <result pre="causes the disease COVIDâ€�19, which manifests as a severe acute" exact="respiratory" post="illness that can be complicated by acute respiratory distress"/>
  <result pre="a severe acute respiratory illness that can be complicated by" exact="acute" post="respiratory distress syndrome (ARDS), multiorgan failure and even death.3"/>
  <result pre="severe acute respiratory illness that can be complicated by acute" exact="respiratory" post="distress syndrome (ARDS), multiorgan failure and even death.3 Following"/>
  <result pre="respiratory illness that can be complicated by acute respiratory distress" exact="syndrome" post="(ARDS), multiorgan failure and even death.3 Following rapid spread"/>
  <result pre="million confirmed cases across more than 200 countries with a" exact="total" post="death count greater than 100Â 000 at the time"/>
  <result pre="regarding the impact of COVIDâ€�19 on patients with IBD. The" exact="primary" post="management of IBD involves treating uncontrolled inflammation with a"/>
  <result pre="patients with IBD. The primary management of IBD involves treating" exact="uncontrolled" post="inflammation with a significant number of patients requiring immuneâ€�based"/>
  <result pre="targeted small molecule therapies.5 However, these therapies, in addition to" exact="malnutrition" post="which can complicate IBD, may weaken the immune system"/>
  <result pre="system and potentially place IBD patients at increased risk of" exact="infections" post="and infectious complications.6 Consequently, there is a concern that"/>
  <result pre="potentially place IBD patients at increased risk of infections and" exact="infectious" post="complications.6 Consequently, there is a concern that IBD patients"/>
  <result pre="OC43Â (HCoVâ€�OC43), Human coronavirus HKU1Â (HCoVâ€�HKU1), Human coronavirus NL63Â (HCoVâ€�NL63)," exact="Severe" post="Acute Respiratory Syndrome Coronavirus (SARSâ€�CoV), Middle Eastern Respiratory Syndrome"/>
  <result pre="(HCoVâ€�OC43), Human coronavirus HKU1Â (HCoVâ€�HKU1), Human coronavirus NL63Â (HCoVâ€�NL63), Severe" exact="Acute" post="Respiratory Syndrome Coronavirus (SARSâ€�CoV), Middle Eastern Respiratory Syndrome Coronavirus"/>
  <result pre="Human coronavirus HKU1Â (HCoVâ€�HKU1), Human coronavirus NL63Â (HCoVâ€�NL63), Severe Acute" exact="Respiratory" post="Syndrome Coronavirus (SARSâ€�CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERSâ€�CoV)"/>
  <result pre="coronavirus HKU1Â (HCoVâ€�HKU1), Human coronavirus NL63Â (HCoVâ€�NL63), Severe Acute Respiratory" exact="Syndrome" post="Coronavirus (SARSâ€�CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERSâ€�CoV) and"/>
  <result pre="NL63Â (HCoVâ€�NL63), Severe Acute Respiratory Syndrome Coronavirus (SARSâ€�CoV), Middle Eastern" exact="Respiratory" post="Syndrome Coronavirus (MERSâ€�CoV) and Severe Acute Respiratory Syndrome Coronavirus"/>
  <result pre="(HCoVâ€�NL63), Severe Acute Respiratory Syndrome Coronavirus (SARSâ€�CoV), Middle Eastern Respiratory" exact="Syndrome" post="Coronavirus (MERSâ€�CoV) and Severe Acute Respiratory Syndrome Coronavirus 2"/>
  <result pre="Syndrome Coronavirus (SARSâ€�CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERSâ€�CoV) and" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARSâ€�CoVâ€�2). 9 These viruses"/>
  <result pre="Coronavirus (SARSâ€�CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERSâ€�CoV) and Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARSâ€�CoVâ€�2). 9 These viruses are"/>
  <result pre="(SARSâ€�CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERSâ€�CoV) and Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARSâ€�CoVâ€�2). 9 These viruses are all"/>
  <result pre="Middle Eastern Respiratory Syndrome Coronavirus (MERSâ€�CoV) and Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARSâ€�CoVâ€�2). 9 These viruses are all known"/>
  <result pre="2 (SARSâ€�CoVâ€�2). 9 These viruses are all known to cause" exact="respiratory" post="symptoms ranging broadly in severity, both between the different"/>
  <result pre="(CFR) of up to 30%, but appears to have a" exact="lower" post="personâ€�toâ€�person transmission, limiting its global impact.5 There are still"/>
  <result pre="SARSâ€�CoVâ€�2, the virus previously known as novel 2019â€�coronavirus, causes the" exact="disease" post="COVIDâ€�19. It was first discovered following the reports of"/>
  <result pre="was first discovered following the reports of an outbreak of" exact="pneumonia" post="in China, with initial infections linked to a single"/>
  <result pre="reports of an outbreak of pneumonia in China, with initial" exact="infections" post="linked to a single seafood market.1, 13 Genetic studies"/>
  <result pre="transmission is thought to have been facilitated by an animal" exact="intermediate" post="host, currently hypothesised to be a pangolin.15 3.1 Transmission"/>
  <result pre="host serine protease TMPRSS2 for S priming allowing fusion of" exact="viral" post="and cellular membranes and viral entry into the cell.21"/>
  <result pre="S priming allowing fusion of viral and cellular membranes and" exact="viral" post="entry into the cell.21 Once a person develops initial"/>
  <result pre="the cell.21 Once a person develops initial symptoms of COVIDâ€�19," exact="respiratory" post="viral shedding occurs for a median of 20Â days"/>
  <result pre="cell.21 Once a person develops initial symptoms of COVIDâ€�19, respiratory" exact="viral" post="shedding occurs for a median of 20Â days in"/>
  <result pre="or infectivity; a study of nine COVIDâ€�19 patients demonstrated that" exact="infectious" post="virus was only isolated from samples taken before day"/>
  <result pre="taken before day 8 of symptom onset despite ongoing high" exact="viral" post="loads and shedding after this time point.27 Asymptomatic people"/>
  <result pre="to 50% of stool specimens and can remain positive for" exact="viral" post="RNA following negative respiratory samples in more than 20%"/>
  <result pre="specimens and can remain positive for viral RNA following negative" exact="respiratory" post="samples in more than 20% of SARSâ€�CoVâ€�2 patients.19, 22,"/>
  <result pre="diarrhoea/vomiting/abdominal pain (20%), generalised myalgia/arthralgia (15%), headache (14%), malaise and" exact="bilateral" post="interstitial pneumonia.15, 19, 30 COVIDâ€�19 pneumonia manifests with chest"/>
  <result pre="headache (14%), malaise and bilateral interstitial pneumonia.15, 19, 30 COVIDâ€�19" exact="pneumonia" post="manifests with chest CT imaging abnormalities, even in asymptomatic"/>
  <result pre="and bilateral interstitial pneumonia.15, 19, 30 COVIDâ€�19 pneumonia manifests with" exact="chest" post="CT imaging abnormalities, even in asymptomatic patients, with rapid"/>
  <result pre="imaging abnormalities, even in asymptomatic patients, with rapid evolution from" exact="focal" post="unilateral to diffuse bilateral groundâ€�glass opacities that progress to"/>
  <result pre="abnormalities, even in asymptomatic patients, with rapid evolution from focal" exact="unilateral" post="to diffuse bilateral groundâ€�glass opacities that progress to or"/>
  <result pre="in asymptomatic patients, with rapid evolution from focal unilateral to" exact="diffuse" post="bilateral groundâ€�glass opacities that progress to or coâ€�exist with"/>
  <result pre="asymptomatic patients, with rapid evolution from focal unilateral to diffuse" exact="bilateral" post="groundâ€�glass opacities that progress to or coâ€�exist with consolidations"/>
  <result pre="to be clarified, enteric symptoms may occur due to malabsorption" exact="secondary" post="to direct damage of the invaded enterocyte in the"/>
  <result pre="damage of the invaded enterocyte in the setting of a" exact="viral" post="infection.18 Furthermore, there is a recent case report of"/>
  <result pre="is a recent case report of a possible SARSâ€�CoVâ€�2 gastrointestinal" exact="infection" post="causing acute haemorrhagic colitis and signalling COVIDâ€�19 disease.31 It"/>
  <result pre="recent case report of a possible SARSâ€�CoVâ€�2 gastrointestinal infection causing" exact="acute" post="haemorrhagic colitis and signalling COVIDâ€�19 disease.31 It is not"/>
  <result pre="report of a possible SARSâ€�CoVâ€�2 gastrointestinal infection causing acute haemorrhagic" exact="colitis" post="and signalling COVIDâ€�19 disease.31 It is not clear if"/>
  <result pre="COVIDâ€�19 disease.31 It is not clear if gastrointestinal symptom rates" exact="secondary" post="to COVIDâ€�19 differ in patients with IBD but if"/>
  <result pre="if an IBD patients presents with worsening gastrointestinal symptoms, COVIDâ€�19" exact="infection" post="should be considered as a differential. 3.3 Demographics The"/>
  <result pre="is male. Healthcare workers may be at increased risk of" exact="infection" post="secondary to close contact with infected patients and exposure"/>
  <result pre="male. Healthcare workers may be at increased risk of infection" exact="secondary" post="to close contact with infected patients and exposure to"/>
  <result pre="children under the age of 18Â years have a low" exact="infection" post="rate (2.4%), with a large proportion being identified through"/>
  <result pre="through contact tracing in adults rather than through symptomatology.16 3.4" exact="Disease" post="course The median incubation period for SARSâ€�CoVâ€�2 is 4â€�5Â"/>
  <result pre="surmise that most cases of COVIDâ€�19 have mild to moderate" exact="disease" post="(80%) with 13.8% experiencing severe disease defined by the"/>
  <result pre="have mild to moderate disease (80%) with 13.8% experiencing severe" exact="disease" post="defined by the following signs and symptoms within 24â€�48Â"/>
  <result pre="24â€�48Â hours: shortness of breath; tachypnoea &amp;gt;30 breaths per minute;" exact="hypoxia" post="&amp;lt;93%; hypoxaemia with PaO2/FiO2 ratioÂ 50% of the lung"/>
  <result pre="hypoxaemia with PaO2/FiO2 ratioÂ 50% of the lung field.16 Critical" exact="infections" post="occur in 6.1% and are exemplified by septic shock,"/>
  <result pre="field.16 Critical infections occur in 6.1% and are exemplified by" exact="septic shock," post="respiratory failure and/or multiorgan failure.1, 16 Approximately one quarter"/>
  <result pre="infections occur in 6.1% and are exemplified by septic shock," exact="respiratory" post="failure and/or multiorgan failure.1, 16 Approximately one quarter of"/>
  <result pre="of hospitalised patients require intensive care and 4.3% die.1 The" exact="primary" post="reason for transfer to ICU is the development of"/>
  <result pre="not been fully elucidated. Healthcare professionals are at greater risk" exact="secondary" post="to increased exposure32 and it is thought that smoking"/>
  <result pre="vs 51Â years in the overall patient population) and underlying" exact="cardiovascular disease," post="hypertension, chronic pulmonary disease, diabetes and cancer.16, 17, 38"/>
  <result pre="in the overall patient population) and underlying cardiovascular disease, hypertension," exact="chronic" post="pulmonary disease, diabetes and cancer.16, 17, 38 Severe COVIDâ€�19"/>
  <result pre="the overall patient population) and underlying cardiovascular disease, hypertension, chronic" exact="pulmonary" post="disease, diabetes and cancer.16, 17, 38 Severe COVIDâ€�19 is"/>
  <result pre="patient population) and underlying cardiovascular disease, hypertension, chronic pulmonary disease," exact="diabetes" post="and cancer.16, 17, 38 Severe COVIDâ€�19 is less common"/>
  <result pre="disease, hypertension, chronic pulmonary disease, diabetes and cancer.16, 17, 38" exact="Severe" post="COVIDâ€�19 is less common in children with reports suggesting"/>
  <result pre="common in children with reports suggesting approximately 5% develop severe" exact="disease" post="and 0.6% become critical.39 The crude fatality rate is"/>
  <result pre="factors for developing severe/critical COVIDâ€�1917, 19, 116 AgeÂ &amp;gt;Â 50" exact="Diabetes" post="Hypertension Malignancy COPD Smoker Lymphopenia Neutropenia Higher LDH and"/>
  <result pre="for developing severe/critical COVIDâ€�1917, 19, 116 AgeÂ &amp;gt;Â 50 Diabetes" exact="Hypertension" post="Malignancy COPD Smoker Lymphopenia Neutropenia Higher LDH and Dâ€�dimer"/>
  <result pre="116 AgeÂ &amp;gt;Â 50 Diabetes Hypertension Malignancy COPD Smoker Lymphopenia" exact="Neutropenia" post="Higher LDH and Dâ€�dimer levels &amp;gt;1Â Âµg/mL on admission"/>
  <result pre="Further risk factors for death if admitted to ICU17, 116" exact="Tachycardia" post="Lymphopenia Hypoxia Coagulopathy (C) John Wiley &amp;amp; Sons, Ltd,"/>
  <result pre="Ltd, This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  <result pre="COVIDâ€�19 in IBD patients are yet to be determined. For" exact="lower" post="respiratory tract infections with seasonal (nonâ€�COVIDâ€�19) coronavirus, risk factors"/>
  <result pre="in IBD patients are yet to be determined. For lower" exact="respiratory" post="tract infections with seasonal (nonâ€�COVIDâ€�19) coronavirus, risk factors in"/>
  <result pre="patients are yet to be determined. For lower respiratory tract" exact="infections" post="with seasonal (nonâ€�COVIDâ€�19) coronavirus, risk factors in other immunocompromised"/>
  <result pre="patient groups have included age &amp;gt;50Â years, receipt of corticosteroids," exact="lymphopenia" post="and neutropenia.26, 40 For IBD patients, the greatest risk"/>
  <result pre="IBD patients, the greatest risk factor for general immunosuppression and" exact="infections" post="remains pharmacological.41, 42 Nutritional status, coâ€�morbidities, age and disease"/>
  <result pre="and infections remains pharmacological.41, 42 Nutritional status, coâ€�morbidities, age and" exact="disease" post="activity also contribute.42, 43 Of these, malnutrition (OR: 6.26"/>
  <result pre="coâ€�morbidities, age and disease activity also contribute.42, 43 Of these," exact="malnutrition" post="(OR: 6.26 [95% CI: 1.20â€�32.78])41, 42 and disease activity"/>
  <result pre="Of these, malnutrition (OR: 6.26 [95% CI: 1.20â€�32.78])41, 42 and" exact="disease" post="activity (OR: 3.35 [95%CI: 1.23â€�9.23, PÂ =Â 0.02])44 are"/>
  <result pre="0.02])44 are significant nonpharmacological risk factors that are modifiable for" exact="infection" post="and therefore nutritional support and medical treatment aiming for"/>
  <result pre="infection and therefore nutritional support and medical treatment aiming for" exact="disease" post="control should be optimised.41, 42 Furthermore, low vitamin D"/>
  <result pre="and COVIDâ€�19.45, 46 Vitamin D increases antiâ€�inflammatory cytokines and lowers" exact="viral" post="replication, which in turn may reduce proâ€�inflammatory cytokines that"/>
  <result pre="bowel,48 there is also a theoretical increased risk of SARSâ€�CoVâ€�2" exact="infection" post="via the gut in IBD patients. Despite this, there"/>
  <result pre="patients. Despite this, there is no current evidence of increased" exact="infection" post="rates or worse disease severity of COVIDâ€�19 in IBD"/>
  <result pre="is no current evidence of increased infection rates or worse" exact="disease" post="severity of COVIDâ€�19 in IBD patients. Indeed, so far,"/>
  <result pre="of 11 April 2020. At time of writing, 457 (270" exact="Crohn's disease" post="[CD]; 185 UC/unspecified) cases of COVIDâ€�19 in IBD had"/>
  <result pre="11 April 2020. At time of writing, 457 (270 Crohn's" exact="disease" post="[CD]; 185 UC/unspecified) cases of COVIDâ€�19 in IBD had"/>
  <result pre="had been reported with 26% of CD and 36% of" exact="ulcerative colitis" post="(UC) patients requiring hospitalisation and 3% of CD and"/>
  <result pre="been reported with 26% of CD and 36% of ulcerative" exact="colitis" post="(UC) patients requiring hospitalisation and 3% of CD and"/>
  <result pre="reported.50 This appears to be a notable underâ€�representation of COVIDâ€�19" exact="infection" post="in IBD patients compared to the prevalence of IBD"/>
  <result pre="the community. As yet, it is unclear if this is" exact="secondary" post="to low COVIDâ€�19 infection rates or to significant underâ€�reporting"/>
  <result pre="it is unclear if this is secondary to low COVIDâ€�19" exact="infection" post="rates or to significant underâ€�reporting of COVIDâ€�19 infection in"/>
  <result pre="low COVIDâ€�19 infection rates or to significant underâ€�reporting of COVIDâ€�19" exact="infection" post="in IBD patients. 3.6 Diagnosis A diagnosis of COVIDâ€�19"/>
  <result pre="Of note, a subgroup of patients may present with mild" exact="disease" post="marked by the presence of diarrhoea initially and these"/>
  <result pre="often experience delayed diagnosis compared to those that present with" exact="respiratory" post="symptoms.51 Biochemical markers of COVIDâ€�19 include lymphopenia, thrombocytopenia and"/>
  <result pre="present with respiratory symptoms.51 Biochemical markers of COVIDâ€�19 include lymphopenia," exact="thrombocytopenia" post="and leukopenia as well as elevated Câ€�reactive protein (CRP),"/>
  <result pre="respiratory symptoms.51 Biochemical markers of COVIDâ€�19 include lymphopenia, thrombocytopenia and" exact="leukopenia" post="as well as elevated Câ€�reactive protein (CRP), which may"/>
  <result pre="of their history if they are admitted to hospital with" exact="acute" post="respiratory illness or unexplained fever. Diagnosis of COVIDâ€�19 is"/>
  <result pre="their history if they are admitted to hospital with acute" exact="respiratory" post="illness or unexplained fever. Diagnosis of COVIDâ€�19 is via"/>
  <result pre="important to ensure that routine local protocols for testing in" exact="acute" post="pneumonia/pneumonitis are also followed, such as bacterial cultures, urinary"/>
  <result pre="for testing in acute pneumonia/pneumonitis are also followed, such as" exact="bacterial" post="cultures, urinary antigen testing, acute and convalescent serology and"/>
  <result pre="are also followed, such as bacterial cultures, urinary antigen testing," exact="acute" post="and convalescent serology and respiratory virus panels. At this"/>
  <result pre="bacterial cultures, urinary antigen testing, acute and convalescent serology and" exact="respiratory" post="virus panels. At this stage, faecal sampling is not"/>
  <result pre="test for COVIDâ€�19 must be immediately notified to the relevant" exact="communicable diseases" post="agency.52 4 MANAGEMENT OF IMMUNOSUPPRESSION WITH COVIDâ€�19 Despite a"/>
  <result pre="WITH COVIDâ€�19 Despite a lack of evidence demonstrating any increased" exact="susceptibility to" post="COVIDâ€�19,50 medications used in the management of IBD have"/>
  <result pre="of IBD have been shown to increase the risk of" exact="respiratory" post="tract infections and serious infections to varying degrees (TableÂ"/>
  <result pre="have been shown to increase the risk of respiratory tract" exact="infections" post="and serious infections to varying degrees (TableÂ 2). However,"/>
  <result pre="to increase the risk of respiratory tract infections and serious" exact="infections" post="to varying degrees (TableÂ 2). However, theoretically, there may"/>
  <result pre="cytokine storm resulting in ARDS. Table 2 IBD medications and" exact="infection" post="risk Â Risk of respiratory tract infections Risk of"/>
  <result pre="Table 2 IBD medications and infection risk Â Risk of" exact="respiratory" post="tract infections Risk of serious infections Steroids Prednisolone URTI"/>
  <result pre="IBD medications and infection risk Â Risk of respiratory tract" exact="infections" post="Risk of serious infections Steroids Prednisolone URTI for influenza"/>
  <result pre="risk Â Risk of respiratory tract infections Risk of serious" exact="infections" post="Steroids Prednisolone URTI for influenza compared to placebo OR"/>
  <result pre="OR 3.32 (95% CI 0.13â€�84.9) compared to prednisolone 69 Immunomodulators" exact="Thiopurines" post="2.1 per patientâ€�years70 OR 0.143 (95% CI 0.43â€�4.76) compared"/>
  <result pre="to 3.1)/100 patientâ€�years (in RA)123 Abbreviations: HR, hazard ratio; LRTI," exact="lower" post="respiratory tract infection; OR, odds ratio; RA, rheumatoid arthritis;"/>
  <result pre="3.1)/100 patientâ€�years (in RA)123 Abbreviations: HR, hazard ratio; LRTI, lower" exact="respiratory" post="tract infection; OR, odds ratio; RA, rheumatoid arthritis; CI,"/>
  <result pre="ratio; LRTI, lower respiratory tract infection; OR, odds ratio; RA," exact="rheumatoid arthritis;" post="CI, confidence interval; RR, relative risk; URTI, upper respiratory"/>
  <result pre="RA, rheumatoid arthritis; CI, confidence interval; RR, relative risk; URTI," exact="upper respiratory tract infection." post="(C) John Wiley &amp;amp; Sons, Ltd, This article is"/>
  <result pre="rheumatoid arthritis; CI, confidence interval; RR, relative risk; URTI, upper" exact="respiratory" post="tract infection. (C) John Wiley &amp;amp; Sons, Ltd, This"/>
  <result pre="Ltd, This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  <result pre="of these medications being associated with an increased risk of" exact="infection" post="and studies of large cohorts evaluating the safety profile"/>
  <result pre="turning off multiple inflammatory genes. In patients with COVIDâ€�19, a" exact="systemic" post="inflammatory response syndrome can perpetuate lung injury with persistent"/>
  <result pre="inflammatory genes. In patients with COVIDâ€�19, a systemic inflammatory response" exact="syndrome" post="can perpetuate lung injury with persistent inflammation resulting in"/>
  <result pre="can perpetuate lung injury with persistent inflammation resulting in ongoing" exact="pulmonary" post="damage even subsequent to viral suppression.54 Corticosteroids have therefore"/>
  <result pre="persistent inflammation resulting in ongoing pulmonary damage even subsequent to" exact="viral" post="suppression.54 Corticosteroids have therefore been trialled in the treatment"/>
  <result pre="of coronavirusâ€™, including COVIDâ€�19.54, 55, 56 However corticosteroids in these" exact="infections" post="have no demonstrated benefit; rather, steroids have been shown"/>
  <result pre="PÂ =Â 0.12) but were associated with delayed clearance of" exact="viral" post="RNA from respiratory tract secretions (adjusted hazard ratio 0.4,"/>
  <result pre="but were associated with delayed clearance of viral RNA from" exact="respiratory" post="tract secretions (adjusted hazard ratio 0.4, 95% CI 0.2â€�0.7;"/>
  <result pre="corticosteroid treatment was of no clinical benefit in regard to" exact="infection" post="resolution but was associated with an increased risk of"/>
  <result pre="associated with an increased risk of psychosis,57 delayed clearance of" exact="viral" post="RNA,58 diabetes59 and avascular necrosis.60 Finally, in a systematic"/>
  <result pre="length of stay in intensive care, an increased rate of" exact="secondary" post="bacterial and fungal infections and an increase in mortality"/>
  <result pre="of stay in intensive care, an increased rate of secondary" exact="bacterial" post="and fungal infections and an increase in mortality compared"/>
  <result pre="intensive care, an increased rate of secondary bacterial and fungal" exact="infections" post="and an increase in mortality compared to those who"/>
  <result pre="however, steroids are widely known to increase the risk of" exact="opportunistic infections" post="and respiratory infections including influenza, pneumonia and severe infections"/>
  <result pre="steroids are widely known to increase the risk of opportunistic" exact="infections" post="and respiratory infections including influenza, pneumonia and severe infections"/>
  <result pre="widely known to increase the risk of opportunistic infections and" exact="respiratory" post="infections including influenza, pneumonia and severe infections and are"/>
  <result pre="known to increase the risk of opportunistic infections and respiratory" exact="infections" post="including influenza, pneumonia and severe infections and are associated"/>
  <result pre="the risk of opportunistic infections and respiratory infections including influenza," exact="pneumonia" post="and severe infections and are associated with an increased"/>
  <result pre="opportunistic infections and respiratory infections including influenza, pneumonia and severe" exact="infections" post="and are associated with an increased risk of hospitalisation"/>
  <result pre="62, 63, 64 Therefore, due to the possible risks with" exact="systemic" post="corticosteroids, IBD patients should taper their systemic corticosteroids to"/>
  <result pre="possible risks with systemic corticosteroids, IBD patients should taper their" exact="systemic" post="corticosteroids to the lowest tolerated dose with complete weaning"/>
  <result pre="taper their systemic corticosteroids to the lowest tolerated dose with" exact="complete" post="weaning where possible. Patients should also be advised not"/>
  <result pre="where possible. Patients should also be advised not to selfâ€�commence" exact="systemic" post="corticosteroids to control IBD symptoms unless under the direction"/>
  <result pre="Data for budesonide and beclomethasone, locally acting corticosteroids with low" exact="systemic" post="bioavailability, demonstrate that these medications are associated with significantly"/>
  <result pre="are associated with significantly fewer side effects when compared to" exact="systemic" post="corticosteroids with adverse events similar to placebo.65, 66, 67,"/>
  <result pre="with corticosteroids is associated with an increased risk of COVIDâ€�19" exact="infection" post="or complications. Where possible, corticosteroid use should be avoided"/>
  <result pre="causing apoptosis of T cells, integral in host defence against" exact="viral" post="pathogens.70 Thiopurines (azathioprine and mercaptopurine) have been associated with"/>
  <result pre="of T cells, integral in host defence against viral pathogens.70" exact="Thiopurines" post="(azathioprine and mercaptopurine) have been associated with an increased"/>
  <result pre="being associated with up to a fivefold increased risk of" exact="herpes" post="simplex virus lesions and significant worsening of viral warts.71"/>
  <result pre="risk of herpes simplex virus lesions and significant worsening of" exact="viral" post="warts.71 However there is limited evidence that they increase"/>
  <result pre="lesions and significant worsening of viral warts.71 However there is" exact="limited" post="evidence that they increase the risk of either upper"/>
  <result pre="is limited evidence that they increase the risk of either" exact="upper" post="respiratory tract infections or pulmonary infections.70, 71 In addition,"/>
  <result pre="limited evidence that they increase the risk of either upper" exact="respiratory" post="tract infections or pulmonary infections.70, 71 In addition, mercaptopurine"/>
  <result pre="that they increase the risk of either upper respiratory tract" exact="infections" post="or pulmonary infections.70, 71 In addition, mercaptopurine has been"/>
  <result pre="increase the risk of either upper respiratory tract infections or" exact="pulmonary" post="infections.70, 71 In addition, mercaptopurine has been shown to"/>
  <result pre="been shown to inhibit one of the proteases essential to" exact="viral" post="maturation of MERSâ€�CoV in vitro, although no further animalâ€�based"/>
  <result pre="Methotrexate has variably been demonstrated to increase the risk of" exact="infections" post="in patients with inflammatory diseases. Reassuringly, a recent systematic"/>
  <result pre="a recent systematic review reassuringly found that in the nonrheumatoid" exact="arthritis" post="inflammatory disease population, there was not an increased risk"/>
  <result pre="systematic review reassuringly found that in the nonrheumatoid arthritis inflammatory" exact="disease" post="population, there was not an increased risk of infection"/>
  <result pre="inflammatory disease population, there was not an increased risk of" exact="infection" post="with methotrexate (1.03, 95% CI0.82â€�1.3).73 This applied similarly to"/>
  <result pre="infection with methotrexate (1.03, 95% CI0.82â€�1.3).73 This applied similarly to" exact="respiratory" post="infections specifically.74 Immunomodulators No clear evidence of increased risk"/>
  <result pre="with methotrexate (1.03, 95% CI0.82â€�1.3).73 This applied similarly to respiratory" exact="infections" post="specifically.74 Immunomodulators No clear evidence of increased risk of"/>
  <result pre="infections specifically.74 Immunomodulators No clear evidence of increased risk of" exact="lower" post="respiratory tract infections with immunomodulators Some evidence that thiopurines"/>
  <result pre="specifically.74 Immunomodulators No clear evidence of increased risk of lower" exact="respiratory" post="tract infections with immunomodulators Some evidence that thiopurines impair"/>
  <result pre="No clear evidence of increased risk of lower respiratory tract" exact="infections" post="with immunomodulators Some evidence that thiopurines impair viral immunity"/>
  <result pre="respiratory tract infections with immunomodulators Some evidence that thiopurines impair" exact="viral" post="immunity and mixed evidence that that they have some"/>
  <result pre="Weigh risks and benefits, but most patients can continue on" exact="stable" post="dose. In older patients, those in sustained remission and"/>
  <result pre="Antiâ€�TNF agents have been shown to increase the risk of" exact="upper" post="and lower respiratory tract infections, as well as serious"/>
  <result pre="have been shown to increase the risk of upper and" exact="lower" post="respiratory tract infections, as well as serious and opportunistic"/>
  <result pre="been shown to increase the risk of upper and lower" exact="respiratory" post="tract infections, as well as serious and opportunistic pulmonary"/>
  <result pre="lower respiratory tract infections, as well as serious and opportunistic" exact="pulmonary" post="infections.62, 75, 76 Compared with antiâ€�TNF monotherapy, risk of"/>
  <result pre="infections.62, 75, 76 Compared with antiâ€�TNF monotherapy, risk of serious" exact="infections" post="increases with combination of antiâ€�TNF and an immunosuppressive agent"/>
  <result pre="that did not separate monoâ€&quot;or combinationâ€&quot;antiâ€�TNF therapies, the risk of" exact="pneumonia" post="was only slightly increased in patients receiving a TNF"/>
  <result pre="and the antiâ€�integrin therapy, vedolizumab. Reassuringly, the risk of severe" exact="respiratory" post="tract infections, severe infections in general or opportunistic infections"/>
  <result pre="vedolizumab. Reassuringly, the risk of severe respiratory tract infections, severe" exact="infections" post="in general or opportunistic infections does not appear to"/>
  <result pre="of severe respiratory tract infections, severe infections in general or" exact="opportunistic infections" post="does not appear to be increased in longâ€�term followâ€�up"/>
  <result pre="severe respiratory tract infections, severe infections in general or opportunistic" exact="infections" post="does not appear to be increased in longâ€�term followâ€�up"/>
  <result pre="There is a theoretical concern of an increased risk of" exact="respiratory" post="infections, and hence COVIDâ€�19, with vedolizumab treatment as vedolizumab"/>
  <result pre="metaâ€�analysis failed to demonstrate a significant difference in rates of" exact="nasopharyngitis" post="between antiâ€�TNF agents and vedolizumab, and multiple studies on"/>
  <result pre="have demonstrated that there is no increased risk of respiratory," exact="systemic" post="or serious infections in patients on vedolizumab over placebo"/>
  <result pre="there is no increased risk of respiratory, systemic or serious" exact="infections" post="in patients on vedolizumab over placebo .83, 84, 85,"/>
  <result pre="deep remission and/or older, consider withholding/ceasing immunomodulator therapy to reduce" exact="infection" post="risk. If possible utilise therapeutic drug monitoring to guide"/>
  <result pre="in the management of UC, particularly in those patients with" exact="disease" post="refractory to biologic agents. Tofacitinib may impair immunity to"/>
  <result pre="disease refractory to biologic agents. Tofacitinib may impair immunity to" exact="viral" post="infections and has been shown to increase the risk"/>
  <result pre="refractory to biologic agents. Tofacitinib may impair immunity to viral" exact="infections" post="and has been shown to increase the risk of"/>
  <result pre="infections and has been shown to increase the risk of" exact="herpes zoster" post="(HZ) infection, with 5.6% of UC patients developing HZ"/>
  <result pre="and has been shown to increase the risk of herpes" exact="zoster" post="(HZ) infection, with 5.6% of UC patients developing HZ"/>
  <result pre="However, longâ€�term followâ€�up of patients treated with this agent for" exact="rheumatoid arthritis" post="have described rates of URTI (18.8%) and nasopharyngitis (14.6%)"/>
  <result pre="longâ€�term followâ€�up of patients treated with this agent for rheumatoid" exact="arthritis" post="have described rates of URTI (18.8%) and nasopharyngitis (14.6%)"/>
  <result pre="for rheumatoid arthritis have described rates of URTI (18.8%) and" exact="nasopharyngitis" post="(14.6%) comparable to that of antiâ€�TNFs.90 Serious infection was"/>
  <result pre="(18.8%) and nasopharyngitis (14.6%) comparable to that of antiâ€�TNFs.90 Serious" exact="infection" post="was found to be increased with tofacitinib in the"/>
  <result pre="phase II, III and LTE studies, 259 patients had serious" exact="infections" post="(3.09 events per 100 PY [95% CI 2.73, 3.49]),"/>
  <result pre="100 PY [95% CI 2.73, 3.49]), and the most common" exact="infection" post="was pneumonia.92 Higher doses of 10Â mg twice daily"/>
  <result pre="mg twice daily, age &amp;gt;65Â years, corticosteroids &amp;gt;7.5Â mg/d and" exact="diabetes" post="were also independent factors associated with increased serious infection"/>
  <result pre="and diabetes were also independent factors associated with increased serious" exact="infection" post="risk.92, 93 Therefore, patients on tofacitinib should be maintained"/>
  <result pre="93 Therefore, patients on tofacitinib should be maintained on the" exact="lower" post="5Â mg twice daily dose compared to 10Â mg"/>
  <result pre="weaned off corticosteroids. Interestingly, baricitinib, a JAK inhibitor used in" exact="rheumatoid arthritis," post="has a potential therapeutic role in the management of"/>
  <result pre="severity of the infection.94 JAK inhibitors JAK inhibitors may impair" exact="viral" post="immunity. Use lowest effective dose to maintain remission: Where"/>
  <result pre="patient clears the infection. 4.6 Recommencement of medications following COVIDâ€�19" exact="infection" post="If a patient is exposed to or gets infected"/>
  <result pre="their IBD medication, recommencement of medication can occur once the" exact="infection" post="has been cleared. To clear a patient of COVIDâ€�19:"/>
  <result pre="be cleared if there is clinical improvement in symptoms and" exact="complete" post="resolution of fever for at LEAST 3Â days.95 It"/>
  <result pre="body so the utility of withholding these medications in the" exact="short" post="term is likely to be limited. (See Table 3)."/>
  <result pre="two elimination halfâ€�lives 99% drug eliminated after seven elimination halfâ€�lives" exact="Thiopurines" post="(Azathioprine and Mercaptopurine) t1/2:6â€�TGN and 6â€�MMP in RBCÂ =Â"/>
  <result pre="2â€�3Â weeks Low volume of distribution (3â€�6L/kg) and very low" exact="systemic" post="clearance of 11â€�15ml/hr, mean infliximab is predominantly in the"/>
  <result pre="Ltd, This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  <result pre="gastroenterologists should regularly review local, institutional and international recommendations. Despite" exact="limited" post="data, patients with IBD are theoretically at increased risk"/>
  <result pre="Optimise health and treat malnutrition: Nutrition should be optimised as" exact="malnutrition" post="can disrupt the innate immune response, including complement and"/>
  <result pre="and mucosal secretory antibody formation, and is associated with increased" exact="infection" post="risk in IBD patients.96 Smoking has been associated with"/>
  <result pre="occur and a single nurse per patient arranged to prevent" exact="infection" post="spread. Finally, where possible, infliximab infusions should be converted"/>
  <result pre="Management of COVIDâ€�19 predominantly focuses on supportive care and treating" exact="secondary" post="complications. The highly pathogenic nature of COVIDâ€�19 and the"/>
  <result pre="created a master protocol for a multicentre, adaptive, randomised, double" exact="blind" post="placebo controlled trial of the safety and efficacy of"/>
  <result pre="prolong PR interval. Rare reports of 2nd and 3rd degree" exact="atrioventricular block" post="in patients with underlying risk factors Chloroquine/Hydroxychloroquine 200Â mg"/>
  <result pre="accumulation of 6â€�methylthioinosine monophosphate (6â€�MTIMP), which has been associated with" exact="myelotoxicity" post="Favipiravir Chinese Clinical Trials Registry ID: ChiCTR2000029600 favipiravir plus"/>
  <result pre="Ltd, This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  <result pre="Metabolised by CYP3A4, CYP3A5*, CYP3A7* Substrate: Pâ€�glycoprotein #Not clinically relevant" exact="Thiopurines" post="(azathioprine/ mercaptopurine) Metabolised by: TMPT, HGPRT, XO Methotrexate Transported"/>
  <result pre="by: TMPT, HGPRT, XO Methotrexate Transported into the cell by:" exact="Reduced" post="folate carrier 1 Tacrolimus Inhibits: CYP3A4 (weak) Metabolised by"/>
  <result pre="200Â mg three times a day for 10 days â†‘" exact="myelosuppression" post="risk. Recommend ceasing thiopurine in acute severe infection â†‘"/>
  <result pre="for 10 days â†‘ myelosuppression risk. Recommend ceasing thiopurine in" exact="acute" post="severe infection â†‘ myelosuppression risk. Recommend ceasing methotrexate in"/>
  <result pre="days â†‘ myelosuppression risk. Recommend ceasing thiopurine in acute severe" exact="infection" post="â†‘ myelosuppression risk. Recommend ceasing methotrexate in acute severe"/>
  <result pre="myelosuppression risk. Recommend ceasing thiopurine in acute severe infection â†‘" exact="myelosuppression" post="risk. Recommend ceasing methotrexate in acute severe infection â†‘"/>
  <result pre="acute severe infection â†‘ myelosuppression risk. Recommend ceasing methotrexate in" exact="acute" post="severe infection â†‘ risk of QTâ€�interval prolongation. consider baseline"/>
  <result pre="infection â†‘ myelosuppression risk. Recommend ceasing methotrexate in acute severe" exact="infection" post="â†‘ risk of QTâ€�interval prolongation. consider baseline and follow"/>
  <result pre="monitor levels May â†‘ tofacitinib, clinical significance unknown, monitor. Consider" exact="lower" post="dose where appropriate Ribavirin Do not crush â€&quot;known teratogen."/>
  <result pre="capsules or (SAS) product availability â†‘ risk of thiopurine induced" exact="myelosuppression" post="Cease thiopurine â†‘ risk myelosuppression Cease methotrexate Favipiravir Atazanavir"/>
  <result pre="â†‘ risk of thiopurine induced myelosuppression Cease thiopurine â†‘ risk" exact="myelosuppression" post="Cease methotrexate Favipiravir Atazanavir Requires pH &amp;lt;4. Avoid antacids"/>
  <result pre="Ltd, This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  <result pre="of the adenosine nucleotide analogue GSâ€�441524 that incorporates into nascent" exact="viral" post="RNA chains, inhibiting virus infection in a human cell"/>
  <result pre="analogue GSâ€�441524 that incorporates into nascent viral RNA chains, inhibiting" exact="virus infection" post="in a human cell line (human liver cancer Huh"/>
  <result pre="GSâ€�441524 that incorporates into nascent viral RNA chains, inhibiting virus" exact="infection" post="in a human cell line (human liver cancer Huh"/>
  <result pre="chains, inhibiting virus infection in a human cell line (human" exact="liver cancer" post="Huh 7 cells).102, 103 It appears to be effective"/>
  <result pre="inhibiting virus infection in a human cell line (human liver" exact="cancer" post="Huh 7 cells).102, 103 It appears to be effective"/>
  <result pre="animal model use in SARS and MERSâ€�CoV resulted in a" exact="lower" post="risk of ARDS, lower viral load in lung and"/>
  <result pre="SARS and MERSâ€�CoV resulted in a lower risk of ARDS," exact="lower" post="viral load in lung and extrapulmonary tissue and reduced"/>
  <result pre="and MERSâ€�CoV resulted in a lower risk of ARDS, lower" exact="viral" post="load in lung and extrapulmonary tissue and reduced mortality.104,"/>
  <result pre="Chloroquine or hydroxychloroquine Chloroquine is a widely used antiâ€�malarial and" exact="autoimmune disease" post="drug. It has a broad spectrum antiâ€�viral action that"/>
  <result pre="or hydroxychloroquine Chloroquine is a widely used antiâ€�malarial and autoimmune" exact="disease" post="drug. It has a broad spectrum antiâ€�viral action that"/>
  <result pre="exerted on SARSâ€�CoV by inhibiting the preâ€�entry point of the" exact="viral" post="cycle by interfering with viral binding to cell surface,"/>
  <result pre="the preâ€�entry point of the viral cycle by interfering with" exact="viral" post="binding to cell surface, increasing endosomal pH required for"/>
  <result pre="in exacerbation of pneumonia, duration of symptoms and delay in" exact="viral" post="clearance.109 Chloroquine is not accessible in Australia and it"/>
  <result pre="This antiâ€�viral effect has efficacy on influenza (approved use), Ebola," exact="yellow fever," post="chikungunya, norovirus and enterovirus. Activity against COVIDâ€�19 has been"/>
  <result pre="available to patients seeking â€˜naturalâ€™ alternative therapies and in the" exact="absence of" post="clinical evidence, care should be taken when making such"/>
  <result pre="immunosuppression and this may lead to an increased risk of" exact="infection" post="with SARSâ€�CoVâ€�2 and complications arising from COVIDâ€�19. Despite this,"/>
  <result pre="develop COVIDâ€�19, immunosuppressive medications should be withheld where possible until" exact="infection" post="resolution and if a medication trial is being considered"/>
  <result pre="from Rhythm Biosciences for clinical trial support in biomarkers of" exact="colorectal cancer" post="research. Finlay A. MacraeÂ owns stocks and shares in"/>
  <result pre="Rhythm Biosciences for clinical trial support in biomarkers of colorectal" exact="cancer" post="research. Finlay A. MacraeÂ owns stocks and shares in"/>
  <result pre="Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâ€�infected" exact="pneumonia" post="in Wuhan, China. JAMA. 2020. 2collab: World Health Organisation"/>
  <result pre="2013;21:544â€&quot;555.23770275 4GhoshN, PremchandP. A UK cost of care model for" exact="inflammatory bowel disease." post="Frontline Gastroenterol. 2015;6:169â€&quot;174.28839807 5JeongDY, KimS, SonMJ, et al. Induction"/>
  <result pre="4GhoshN, PremchandP. A UK cost of care model for inflammatory" exact="bowel" post="disease. Frontline Gastroenterol. 2015;6:169â€&quot;174.28839807 5JeongDY, KimS, SonMJ, et al."/>
  <result pre="KimS, SonMJ, et al. Induction and maintenance treatment of inflammatory" exact="bowel" post="disease: a comprehensive review. Autoimmun Rev. 2019;18:439â€&quot;454.30844556 6RahierJF, MagroF,"/>
  <result pre="European evidenceâ€�based consensus on the prevention, diagnosis and management of" exact="opportunistic infections" post="in inflammatory bowel disease. J Crohns Colitis. 2014;8:443â€&quot;468.24613021 7WeissSR,"/>
  <result pre="evidenceâ€�based consensus on the prevention, diagnosis and management of opportunistic" exact="infections" post="in inflammatory bowel disease. J Crohns Colitis. 2014;8:443â€&quot;468.24613021 7WeissSR,"/>
  <result pre="on the prevention, diagnosis and management of opportunistic infections in" exact="inflammatory bowel disease." post="J Crohns Colitis. 2014;8:443â€&quot;468.24613021 7WeissSR, Navasâ€�MartinS. Coronavirus pathogenesis and"/>
  <result pre="the prevention, diagnosis and management of opportunistic infections in inflammatory" exact="bowel" post="disease. J Crohns Colitis. 2014;8:443â€&quot;468.24613021 7WeissSR, Navasâ€�MartinS. Coronavirus pathogenesis"/>
  <result pre="2014;8:443â€&quot;468.24613021 7WeissSR, Navasâ€�MartinS. Coronavirus pathogenesis and the emerging pathogen severe" exact="acute" post="respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69:635â€&quot;664.16339739 8LaiMM,"/>
  <result pre="7WeissSR, Navasâ€�MartinS. Coronavirus pathogenesis and the emerging pathogen severe acute" exact="respiratory" post="syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69:635â€&quot;664.16339739 8LaiMM, CavanaghD."/>
  <result pre="Navasâ€�MartinS. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory" exact="syndrome" post="coronavirus. Microbiol Mol Biol Rev. 2005;69:635â€&quot;664.16339739 8LaiMM, CavanaghD. The"/>
  <result pre="reviews. Coronaviruses. Yale J Biol Med. 1974;47:234â€&quot;251.4617423 11collab: Centres for" exact="Disease" post="Control and Prevention . Middle East Respiratory Syndrome (MERS)."/>
  <result pre="11collab: Centres for Disease Control and Prevention . Middle East" exact="Respiratory" post="Syndrome (MERS). 2016 Updated August 2, 2019. https://www.cdc.gov/sars/index.html 12collab:"/>
  <result pre="Centres for Disease Control and Prevention . Middle East Respiratory" exact="Syndrome" post="(MERS). 2016 Updated August 2, 2019. https://www.cdc.gov/sars/index.html 12collab: Centres"/>
  <result pre="(MERS). 2016 Updated August 2, 2019. https://www.cdc.gov/sars/index.html 12collab: Centres for" exact="Disease" post="Control and Prevention . Severe Acute Respiratory Syndrome (SARS)."/>
  <result pre="2019. https://www.cdc.gov/sars/index.html 12collab: Centres for Disease Control and Prevention ." exact="Severe" post="Acute Respiratory Syndrome (SARS). https://www.cdc.gov/sars/index.html. Accessed 15 March, 2020."/>
  <result pre="https://www.cdc.gov/sars/index.html 12collab: Centres for Disease Control and Prevention . Severe" exact="Acute" post="Respiratory Syndrome (SARS). https://www.cdc.gov/sars/index.html. Accessed 15 March, 2020. 13LuH,"/>
  <result pre="12collab: Centres for Disease Control and Prevention . Severe Acute" exact="Respiratory" post="Syndrome (SARS). https://www.cdc.gov/sars/index.html. Accessed 15 March, 2020. 13LuH, StrattonCW,"/>
  <result pre="Centres for Disease Control and Prevention . Severe Acute Respiratory" exact="Syndrome" post="(SARS). https://www.cdc.gov/sars/index.html. Accessed 15 March, 2020. 13LuH, StrattonCW, TangYW."/>
  <result pre="https://www.cdc.gov/sars/index.html. Accessed 15 March, 2020. 13LuH, StrattonCW, TangYW. Outbreak of" exact="pneumonia" post="of unknown etiology in Wuhan, China: the mystery and"/>
  <result pre="the 2019 novel humanâ€�pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting Wuhan. Emerg Microbes Infect. 2020;9:221â€&quot;236.31987001 15ZhangT, WuQ,"/>
  <result pre="2019 novel humanâ€�pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting Wuhan. Emerg Microbes Infect. 2020;9:221â€&quot;236.31987001 15ZhangT, WuQ,"/>
  <result pre="2020. 16collab: World Health Organisation . Report of the WHOâ€�China" exact="Joint" post="Mission on Coronavirus Disease 2019 (COVIDâ€�19). March 16, 2020."/>
  <result pre="Organisation . Report of the WHOâ€�China Joint Mission on Coronavirus" exact="Disease" post="2019 (COVIDâ€�19). March 16, 2020. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf 17GuanWJ, NiZY, HuY,"/>
  <result pre="https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf 17GuanWJ, NiZY, HuY, et al. Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med. 2020. 18GuJ,"/>
  <result pre="et al. Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVIDâ€�19 in Wuhan, China: a retrospective cohort"/>
  <result pre="Lancet. 2020;395:1054â€&quot;1062.32171076 25PrescottJ, FalzaranoD, de WitE, et al. Pathogenicity and" exact="viral" post="shedding of MERSâ€�CoV in immunocompromised rhesus macaques. Front Immunol."/>
  <result pre="ZappettiD, et al. Incidence, significance, and persistence of human coronavirus" exact="infection" post="in hematopoietic stem cell transplant recipients. Bone Marrow Transplant."/>
  <result pre="Nature. 2020. 28RotheC, SchunkM, SothmannP, et al. Transmission of 2019â€�nCoV" exact="infection" post="from an asymptomatic contact in Germany. N Engl J"/>
  <result pre="Med. 2020;382:970â€&quot;971.32003551 29XiaoF, TangM, ZhengX, et al. Evidence for gastrointestinal" exact="infection" post="of SARSâ€�CoVâ€�2. Gastroenterology. 2020;158:1831â€&quot;1833.32142773 30PanL, MuM, YangP, et al."/>
  <result pre="2020;115:766â€&quot;773 (In Press).32287140 31CarvalhoA, AlqusairiR, AdamsA, et al. SARSâ€�CoVâ€�2 gastrointestinal" exact="infection" post="causing hemorrhagic colitis: implications for detection and transmission of"/>
  <result pre="34LauerSA, GrantzKH, BiQ, et al. The incubation period of coronavirus" exact="disease" post="2019 (COVIDâ€�19) from publicly reported confirmed cases: estimation and"/>
  <result pre="36WuZ, McGooganJM. Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVIDâ€�19) outbreak in China: summary of a report"/>
  <result pre="a report of 72314 cases from the Chinese center for" exact="disease" post="control and prevention. JAMA. 2020. 37BrakeSJ, BarnsleyK, LuW, et"/>
  <result pre="J Clin Med. 2020;9:841. 38ChanJâ€�W, YuanS, KokKâ€�H, et al. A" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="2020;9:841. 38ChanJâ€�W, YuanS, KokKâ€�H, et al. A familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating personâ€�toâ€�person transmission:"/>
  <result pre="Pediatrics. 2020. 40HakkiM, RattrayRM, PressRD. The clinical impact of coronavirus" exact="infection" post="in patients with hematologic malignancies and hematopoietic stem cell"/>
  <result pre="Virol. 2015;68:1â€&quot;5.26071326 41TorunerM, LoftusEV, HarmsenWS, et al. Risk factors for" exact="opportunistic infections" post="in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929â€&quot;936.18294633 42ToscaJ,"/>
  <result pre="2015;68:1â€&quot;5.26071326 41TorunerM, LoftusEV, HarmsenWS, et al. Risk factors for opportunistic" exact="infections" post="in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929â€&quot;936.18294633 42ToscaJ,"/>
  <result pre="et al. Risk factors for opportunistic infections in patients with" exact="inflammatory bowel disease." post="Gastroenterology. 2008;134:929â€&quot;936.18294633 42ToscaJ, GarciaN, PascualI, et al. Clinical assessment"/>
  <result pre="al. Risk factors for opportunistic infections in patients with inflammatory" exact="bowel" post="disease. Gastroenterology. 2008;134:929â€&quot;936.18294633 42ToscaJ, GarciaN, PascualI, et al. Clinical"/>
  <result pre="GarciaN, PascualI, et al. Clinical assessment of risk factors for" exact="infection" post="in inflammatory bowel disease patients. Int J Colorectal Dis."/>
  <result pre="et al. Clinical assessment of risk factors for infection in" exact="inflammatory bowel disease" post="patients. Int J Colorectal Dis. 2020;35:491â€&quot;500.31915983 43AberraFN, LichtensteinGR. Methods"/>
  <result pre="al. Clinical assessment of risk factors for infection in inflammatory" exact="bowel" post="disease patients. Int J Colorectal Dis. 2020;35:491â€&quot;500.31915983 43AberraFN, LichtensteinGR."/>
  <result pre="Clinical assessment of risk factors for infection in inflammatory bowel" exact="disease" post="patients. Int J Colorectal Dis. 2020;35:491â€&quot;500.31915983 43AberraFN, LichtensteinGR. Methods"/>
  <result pre="Int J Colorectal Dis. 2020;35:491â€&quot;500.31915983 43AberraFN, LichtensteinGR. Methods to avoid" exact="infections" post="in patients with inflammatory bowel disease. Inflamm Bowel Dis."/>
  <result pre="2020;35:491â€&quot;500.31915983 43AberraFN, LichtensteinGR. Methods to avoid infections in patients with" exact="inflammatory bowel disease." post="Inflamm Bowel Dis. 2005;11:685â€&quot;695.15973124 44WisniewskiA, KirchgesnerJ, SeksikP, et al."/>
  <result pre="43AberraFN, LichtensteinGR. Methods to avoid infections in patients with inflammatory" exact="bowel" post="disease. Inflamm Bowel Dis. 2005;11:685â€&quot;695.15973124 44WisniewskiA, KirchgesnerJ, SeksikP, et"/>
  <result pre="disease. Inflamm Bowel Dis. 2005;11:685â€&quot;695.15973124 44WisniewskiA, KirchgesnerJ, SeksikP, et al." exact="Increased" post="incidence of systemic serious viral infections in patients with"/>
  <result pre="Dis. 2005;11:685â€&quot;695.15973124 44WisniewskiA, KirchgesnerJ, SeksikP, et al. Increased incidence of" exact="systemic" post="serious viral infections in patients with inflammatory bowel disease"/>
  <result pre="44WisniewskiA, KirchgesnerJ, SeksikP, et al. Increased incidence of systemic serious" exact="viral" post="infections in patients with inflammatory bowel disease associates with"/>
  <result pre="KirchgesnerJ, SeksikP, et al. Increased incidence of systemic serious viral" exact="infections" post="in patients with inflammatory bowel disease associates with active"/>
  <result pre="Increased incidence of systemic serious viral infections in patients with" exact="inflammatory bowel disease" post="associates with active disease and use of thiopurines. United"/>
  <result pre="incidence of systemic serious viral infections in patients with inflammatory" exact="bowel" post="disease associates with active disease and use of thiopurines."/>
  <result pre="of systemic serious viral infections in patients with inflammatory bowel" exact="disease" post="associates with active disease and use of thiopurines. United"/>
  <result pre="infections in patients with inflammatory bowel disease associates with active" exact="disease" post="and use of thiopurines. United European Gastroenterology Journal. 2019;2050640619889763."/>
  <result pre="vitamin D supplementation could reduce risk of influenza and COVIDâ€�19" exact="infections" post="and deaths. Nutrients. 2020;12:988. 46PanareseA, ShahiniE. Letter: Covidâ€�19, and"/>
  <result pre="the deregulation of nicotinamide adenine dinucleotide metabolism and CD38 in" exact="inflammatory bowel disease." post="Biomed Res Int. 2019;2019:3950628.31179321 49AnP, MenguaoJ, MegyaoJ, et al."/>
  <result pre="deregulation of nicotinamide adenine dinucleotide metabolism and CD38 in inflammatory" exact="bowel" post="disease. Biomed Res Int. 2019;2019:3950628.31179321 49AnP, MenguaoJ, MegyaoJ, et"/>
  <result pre="Int. 2019;2019:3950628.31179321 49AnP, MenguaoJ, MegyaoJ, et al. Protection of 318" exact="inflammatory bowel disease" post="patients from the outbreak and rapid spread of COVIDâ€�19"/>
  <result pre="2019;2019:3950628.31179321 49AnP, MenguaoJ, MegyaoJ, et al. Protection of 318 inflammatory" exact="bowel" post="disease patients from the outbreak and rapid spread of"/>
  <result pre="49AnP, MenguaoJ, MegyaoJ, et al. Protection of 318 inflammatory bowel" exact="disease" post="patients from the outbreak and rapid spread of COVIDâ€�19"/>
  <result pre="disease patients from the outbreak and rapid spread of COVIDâ€�19" exact="infection" post="in Wuhan, China. Lancet. 2020 (In Press). 50BrennerEJ, UngaroR,"/>
  <result pre="J Gastroenterol. 2020; EPub Ahead of Print. 52collab: Centers for" exact="Disease" post="Control and Prevention . Testing for COVIDâ€�19. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html?CDC_AA_refVal=https%253A%252F%252Fwww.cdc.gov%252Fcoronavirus%252F2019-ncov%252Fclinical-criteria.html. Accessed"/>
  <result pre="al. Corticosteroid therapy for critically Ill patients with middle east" exact="respiratory" post="syndrome. Am J Respir Crit Care Med. 2018;197:757â€&quot;767.29161116 56NiYâ€�N,"/>
  <result pre="Care. 2019;23:99.30917856 57LeeDTS, WingYK, LeungHCM, et al. Factors associated with" exact="psychosis" post="among patients with severe acute respiratory syndrome: a caseâ€�control"/>
  <result pre="et al. Factors associated with psychosis among patients with severe" exact="acute" post="respiratory syndrome: a caseâ€�control study. Clin Infect Dis. 2004;39:1247â€&quot;1249.15486852"/>
  <result pre="al. Factors associated with psychosis among patients with severe acute" exact="respiratory" post="syndrome: a caseâ€�control study. Clin Infect Dis. 2004;39:1247â€&quot;1249.15486852 58LeeN,"/>
  <result pre="early corticosteroid treatment on plasma SARSâ€�associated Coronavirus RNA concentrations in" exact="adult" post="patients. J Clin Virol. 2004;31:304â€&quot;309.15494274 59XiaoJZ, MaL, GaoJ, et"/>
  <result pre="J Clin Virol. 2004;31:304â€&quot;309.15494274 59XiaoJZ, MaL, GaoJ, et al. Glucocorticoidâ€�induced" exact="diabetes" post="in severe acute respiratory syndrome: the impact of high"/>
  <result pre="2004;31:304â€&quot;309.15494274 59XiaoJZ, MaL, GaoJ, et al. Glucocorticoidâ€�induced diabetes in severe" exact="acute" post="respiratory syndrome: the impact of high dosage and duration"/>
  <result pre="59XiaoJZ, MaL, GaoJ, et al. Glucocorticoidâ€�induced diabetes in severe acute" exact="respiratory" post="syndrome: the impact of high dosage and duration of"/>
  <result pre="Ke Za Zhi. 2004;43:179â€&quot;182.15059370 60LiY. Relationship between glucocorticoid receptor and" exact="deficiency" post="syndrome and the regulation of traditional Chinese medicine. Zhong"/>
  <result pre="Za Zhi. 2004;43:179â€&quot;182.15059370 60LiY. Relationship between glucocorticoid receptor and deficiency" exact="syndrome" post="and the regulation of traditional Chinese medicine. Zhong Xi"/>
  <result pre="Jie He Xue Bao. 2004;2:172â€&quot;174.15339435 61TinsleyA, NavabiS, WilliamsED, et al." exact="Increased" post="risk of influenza and influenzaâ€�related complications among 140,480 patients"/>
  <result pre="risk of influenza and influenzaâ€�related complications among 140,480 patients with" exact="inflammatory bowel disease." post="Inflamm Bowel Dis. 2019;25:369â€&quot;376.30020478 62LongMD, MartinC, SandlerRS, KappelmanMD. Increased"/>
  <result pre="of influenza and influenzaâ€�related complications among 140,480 patients with inflammatory" exact="bowel" post="disease. Inflamm Bowel Dis. 2019;25:369â€&quot;376.30020478 62LongMD, MartinC, SandlerRS, KappelmanMD."/>
  <result pre="bowel disease. Inflamm Bowel Dis. 2019;25:369â€&quot;376.30020478 62LongMD, MartinC, SandlerRS, KappelmanMD." exact="Increased" post="risk of pneumonia among patients with inflammatory bowel disease."/>
  <result pre="Bowel Dis. 2019;25:369â€&quot;376.30020478 62LongMD, MartinC, SandlerRS, KappelmanMD. Increased risk of" exact="pneumonia" post="among patients with inflammatory bowel disease. Am J Gastroenterol."/>
  <result pre="MartinC, SandlerRS, KappelmanMD. Increased risk of pneumonia among patients with" exact="inflammatory bowel disease." post="Am J Gastroenterol. 2013;108:240â€&quot;248.23295276 63OrlickaK, BarnesE, CulverEL. Prevention of"/>
  <result pre="SandlerRS, KappelmanMD. Increased risk of pneumonia among patients with inflammatory" exact="bowel" post="disease. Am J Gastroenterol. 2013;108:240â€&quot;248.23295276 63OrlickaK, BarnesE, CulverEL. Prevention"/>
  <result pre="disease. Am J Gastroenterol. 2013;108:240â€&quot;248.23295276 63OrlickaK, BarnesE, CulverEL. Prevention of" exact="infection" post="caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic"/>
  <result pre="of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv" exact="Chronic" post="Dis. 2013;4:167â€&quot;185.23819020 64DorringtonAM, SelingerCP, ParkesGC, et al. The historical"/>
  <result pre="al. The historical role and contemporary use of corticosteroids in" exact="inflammatory bowel disease." post="J Crohns Colitis. 2020. 65SherlockME, SeowCH, SteinhartAH, GriffithsAM. Oral"/>
  <result pre="The historical role and contemporary use of corticosteroids in inflammatory" exact="bowel" post="disease. J Crohns Colitis. 2020. 65SherlockME, SeowCH, SteinhartAH, GriffithsAM."/>
  <result pre="SeowCH, SteinhartAH, GriffithsAM. Oral budesonide for induction of remission in" exact="ulcerative colitis." post="Cochrane Database Syst Rev. 2010;10:CD007698. 66BenchimolEI, SeowCH, OtleyAR. Steinhart"/>
  <result pre="SeowCH, OtleyAR. Steinhart AH. Budesonide for maintenance of remission in" exact="Crohn's disease." post="Cochrane Database Syst Rev. 2009;1:CD002913. 67MangusoF, BennatoR, LombardiG, et"/>
  <result pre="Gastroenterol. 2015;110:708â€&quot;715.25869389 69BonovasS, NikolopoulosGK, LytrasT, et al. Comparative safety of" exact="systemic" post="and lowâ€�bioavailability steroids in inflammatory bowel disease: Systematic review"/>
  <result pre="al. Comparative safety of systemic and lowâ€�bioavailability steroids in inflammatory" exact="bowel" post="disease: Systematic review and network metaâ€�analysis. Br J Clin"/>
  <result pre="2018;84:239â€&quot;251.29057539 70KirchgesnerJ, LemaitreM, CarratF, et al. Risk of serious and" exact="opportunistic infections" post="associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155:337â€&quot;46."/>
  <result pre="70KirchgesnerJ, LemaitreM, CarratF, et al. Risk of serious and opportunistic" exact="infections" post="associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155:337â€&quot;46."/>
  <result pre="Risk of serious and opportunistic infections associated with treatment of" exact="inflammatory bowel diseases." post="Gastroenterology. 2018;155:337â€&quot;46. e10.29655835 71SeksikP, CosnesJ, SokolH, et al. Incidence"/>
  <result pre="of serious and opportunistic infections associated with treatment of inflammatory" exact="bowel" post="diseases. Gastroenterology. 2018;155:337â€&quot;46. e10.29655835 71SeksikP, CosnesJ, SokolH, et al."/>
  <result pre="Gastroenterology. 2018;155:337â€&quot;46. e10.29655835 71SeksikP, CosnesJ, SokolH, et al. Incidence of" exact="benign" post="upper respiratory tract infections, HSV and HPV cutaneous infections"/>
  <result pre="2018;155:337â€&quot;46. e10.29655835 71SeksikP, CosnesJ, SokolH, et al. Incidence of benign" exact="upper" post="respiratory tract infections, HSV and HPV cutaneous infections in"/>
  <result pre="e10.29655835 71SeksikP, CosnesJ, SokolH, et al. Incidence of benign upper" exact="respiratory" post="tract infections, HSV and HPV cutaneous infections in inflammatory"/>
  <result pre="Incidence of benign upper respiratory tract infections, HSV and HPV" exact="cutaneous" post="infections in inflammatory bowel disease patients treated with azathioprine."/>
  <result pre="of benign upper respiratory tract infections, HSV and HPV cutaneous" exact="infections" post="in inflammatory bowel disease patients treated with azathioprine. Aliment"/>
  <result pre="upper respiratory tract infections, HSV and HPV cutaneous infections in" exact="inflammatory bowel disease" post="patients treated with azathioprine. Aliment Pharmacol Ther. 2009;29:1106â€&quot;1113.19222411 72ChengKâ€�W,"/>
  <result pre="respiratory tract infections, HSV and HPV cutaneous infections in inflammatory" exact="bowel" post="disease patients treated with azathioprine. Aliment Pharmacol Ther. 2009;29:1106â€&quot;1113.19222411"/>
  <result pre="tract infections, HSV and HPV cutaneous infections in inflammatory bowel" exact="disease" post="patients treated with azathioprine. Aliment Pharmacol Ther. 2009;29:1106â€&quot;1113.19222411 72ChengKâ€�W,"/>
  <result pre="mycophenolic acid synergistically inhibit the papainâ€�like protease of Middle East" exact="respiratory" post="syndrome coronavirus. Antiviral Res. 2015;115:9â€&quot;16.25542975 73IbrahimA, AhmedM, ConwayR, CareyJJ."/>
  <result pre="acid synergistically inhibit the papainâ€�like protease of Middle East respiratory" exact="syndrome" post="coronavirus. Antiviral Res. 2015;115:9â€&quot;16.25542975 73IbrahimA, AhmedM, ConwayR, CareyJJ. Risk"/>
  <result pre="coronavirus. Antiviral Res. 2015;115:9â€&quot;16.25542975 73IbrahimA, AhmedM, ConwayR, CareyJJ. Risk of" exact="infection" post="with methotrexate therapy in inflammatory diseases: a systematic review"/>
  <result pre="74ConwayR, LowC, CoughlanRJ, et al. Methotrexate use and risk of" exact="lung disease" post="in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic"/>
  <result pre="LowC, CoughlanRJ, et al. Methotrexate use and risk of lung" exact="disease" post="in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic"/>
  <result pre="al. Methotrexate use and risk of lung disease in psoriasis," exact="psoriatic arthritis," post="and inflammatory bowel disease: systematic literature review and metaâ€�analysis"/>
  <result pre="risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory" exact="bowel" post="disease: systematic literature review and metaâ€�analysis of randomised controlled"/>
  <result pre="controlled trials. BMJ. 2015;350:h1269.25770113 75LichtensteinGR, FeaganBG, CohenRD, et al. Serious" exact="infection" post="and mortality in patients with Crohn's disease: more than"/>
  <result pre="Gastroenterol. 2012;107:1409â€&quot;1422.22890223 76ShahED, FaridaJP, SiegelCA, et al. Risk for overall" exact="infection" post="with antiâ€�TNF and antiâ€�integrin agents used in IBD: a"/>
  <result pre="2017;23:570â€&quot;577.28230558 77SinghS, FacciorussoA, DulaiPS, et al. Comparative risk of serious" exact="infections" post="with biologic and/or immunosuppressive therapy in patients with inflammatory"/>
  <result pre="infections with biologic and/or immunosuppressive therapy in patients with inflammatory" exact="bowel" post="diseases: a systematic review and metaâ€�analysis. Clin Gastroenterol Hepatol."/>
  <result pre="metaâ€�analysis. Int J Clin Pract. 2014;68:520â€&quot;528.24548627 79ChengVC, LauSK, WooPC, YuenKY." exact="Severe" post="acute respiratory syndrome coronavirus as an agent of emerging"/>
  <result pre="Int J Clin Pract. 2014;68:520â€&quot;528.24548627 79ChengVC, LauSK, WooPC, YuenKY. Severe" exact="acute" post="respiratory syndrome coronavirus as an agent of emerging and"/>
  <result pre="J Clin Pract. 2014;68:520â€&quot;528.24548627 79ChengVC, LauSK, WooPC, YuenKY. Severe acute" exact="respiratory" post="syndrome coronavirus as an agent of emerging and reemerging"/>
  <result pre="Clin Pract. 2014;68:520â€&quot;528.24548627 79ChengVC, LauSK, WooPC, YuenKY. Severe acute respiratory" exact="syndrome" post="coronavirus as an agent of emerging and reemerging infection."/>
  <result pre="GasinkC, et al. Ustekinumab as induction and maintenance therapy for" exact="Crohn's disease." post="N Engl J Med. 2016;375:1946â€&quot;1960.27959607 81KalbRE, FiorentinoDF, LebwohlMG, et"/>
  <result pre="Med. 2016;375:1946â€&quot;1960.27959607 81KalbRE, FiorentinoDF, LebwohlMG, et al. Risk of serious" exact="infection" post="with biologic and systemic treatment of psoriasis: results from"/>
  <result pre="LebwohlMG, et al. Risk of serious infection with biologic and" exact="systemic" post="treatment of psoriasis: results from the psoriasis longitudinal assessment"/>
  <result pre="with biologic and systemic treatment of psoriasis: results from the" exact="psoriasis" post="longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151:961â€&quot;969.25970800 82HanauerSB,"/>
  <result pre="IMâ€�UNITI: threeâ€�year efficacy, safety, and immunogenicity of ustekinumab treatment of" exact="Crohn's disease." post="J Crohns Colitis. 2020;14:23â€&quot;32.31158271 83ByeWA, JairathV, TravisSPL. Systematic review:"/>
  <result pre="Systematic review: the safety of vedolizumab for the treatment of" exact="inflammatory bowel disease." post="Aliment Pharmacol Ther. 2017;46:3â€&quot;15.28449273 84MockoP, KawalecP, PilcA. Safety profile"/>
  <result pre="review: the safety of vedolizumab for the treatment of inflammatory" exact="bowel" post="disease. Aliment Pharmacol Ther. 2017;46:3â€&quot;15.28449273 84MockoP, KawalecP, PilcA. Safety"/>
  <result pre="PilcA. Safety profile of biologic drugs in the therapy of" exact="Crohn" post="disease: a systematic review and network metaâ€�analysis. Pharmacol Rep."/>
  <result pre="86ColombelJâ€�F, SandsBE, RutgeertsP, et al. The safety of vedolizumab for" exact="ulcerative colitis" post="and Crohn's disease. Gut. 2017;66:839â€&quot;851.26893500 87BourgesD, ChevaleyreC, WangC, et"/>
  <result pre="SandsBE, RutgeertsP, et al. The safety of vedolizumab for ulcerative" exact="colitis" post="and Crohn's disease. Gut. 2017;66:839â€&quot;851.26893500 87BourgesD, ChevaleyreC, WangC, et"/>
  <result pre="et al. The safety of vedolizumab for ulcerative colitis and" exact="Crohn's disease." post="Gut. 2017;66:839â€&quot;851.26893500 87BourgesD, ChevaleyreC, WangC, et al. Differential expression"/>
  <result pre="VermeireS, BalletV, et al. Switch to adalimumab in patients with" exact="Crohn's disease" post="controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut."/>
  <result pre="BalletV, et al. Switch to adalimumab in patients with Crohn's" exact="disease" post="controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut."/>
  <result pre="randomised SWITCH trial. Gut. 2012;61:229â€&quot;234.21948942 89WinthropKL, MelmedGY, VermeireS, et al." exact="Herpes zoster" post="infection in patients with ulcerative colitis receiving tofacitinib. Inflamm"/>
  <result pre="SWITCH trial. Gut. 2012;61:229â€&quot;234.21948942 89WinthropKL, MelmedGY, VermeireS, et al. Herpes" exact="zoster" post="infection in patients with ulcerative colitis receiving tofacitinib. Inflamm"/>
  <result pre="trial. Gut. 2012;61:229â€&quot;234.21948942 89WinthropKL, MelmedGY, VermeireS, et al. Herpes zoster" exact="infection" post="in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel"/>
  <result pre="MelmedGY, VermeireS, et al. Herpes zoster infection in patients with" exact="ulcerative colitis" post="receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258â€&quot;2265.29850873 90WollenhauptJ, LeeEB, CurtisJR,"/>
  <result pre="VermeireS, et al. Herpes zoster infection in patients with ulcerative" exact="colitis" post="receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258â€&quot;2265.29850873 90WollenhauptJ, LeeEB, CurtisJR,"/>
  <result pre="arthritis: final results of a global, openâ€�label, longâ€�term extension study." exact="Arthritis" post="Res Ther. 2019;21:89.30953540 91SandbornWJ, SuC, SandsBE, et al. Tofacitinib"/>
  <result pre="SandsBE, et al. Tofacitinib as induction and maintenance therapy for" exact="ulcerative colitis." post="N Engl J Med. 2017;376:1723â€&quot;1736.28467869 92HarigaiM. Growing evidence of"/>
  <result pre="evidence of the safety of JAK inhibitors in patients with" exact="rheumatoid arthritis." post="Rheumatology (Oxford). 2019;58(Suppl 1):i34â€&quot;i42.30806708 93WeisshofR, Aharoni GolanM, SossenheimerPH, et"/>
  <result pre="antiâ€�inflammatory treatments. Lancet Infect Dis. 2020;20:400â€&quot;402.32113509 95collab: European Centre for" exact="Disease" post="Prevention and Control . Technical Report: Guidance for discharge"/>
  <result pre="Infectionâ€�related hospitalizations are associated with increased mortality in patients with" exact="inflammatory bowel diseases." post="J Crohns Colitis. 2013;7:107â€&quot;112.22440891 97FongMW, GaoH, WongJY, et al."/>
  <result pre="hospitalizations are associated with increased mortality in patients with inflammatory" exact="bowel" post="diseases. J Crohns Colitis. 2013;7:107â€&quot;112.22440891 97FongMW, GaoH, WongJY, et"/>
  <result pre="infliximab infusions are safe and well tolerated in patients with" exact="inflammatory bowel disease." post="Eur J Gastroenterol Hepatol. 2009;21:71â€&quot;75.19060632 101collab: World Health Organisation"/>
  <result pre="infusions are safe and well tolerated in patients with inflammatory" exact="bowel" post="disease. Eur J Gastroenterol Hepatol. 2009;21:71â€&quot;75.19060632 101collab: World Health"/>
  <result pre="COVIDâ€�19 in hospitalized patients.2020. 102AgostiniML, AndresEL, SimsAC, et al. Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GSâ€�5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GSâ€�5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonuclease. mBio. 2018;9. 103WangM, CaoR,"/>
  <result pre="al. Treatment with lopinavir/ritonavir or interferonâ€�beta1b improves outcome of MERSâ€�CoV" exact="infection" post="in a nonhuman primate model of common marmoset. J"/>
  <result pre="2020. http://www.chictr.org.cn/searchprojen.aspx?title=COVID-19%26officialname=%26subjectid=%26secondaryid=%26applier=%26studyleader=%26ethicalcommitteesanction=%26sponsor=%26studyailment=%26studyailmentcode=%26studytype=0%26studystage=0%26studydesign=0%26minstudyexecutetime=%26maxstudyexecutetime=%26recruitmentstatus=0%26gender=0%26agreetosign=%26secsponsor=%26regno=%26regstatus=0%26country=%26province=%26city=%26institution=%26institutionlevel=%26measure=%26intercode=%26sourceofspends=%26createyear=0%26isuploadrf=%26whetherpublic=%26btngo=btn%26verifycode=%26page=1 115SchwartzJ, KingCâ€�C, YenMâ€�Y.Protecting healthcare workers during the coronavirus" exact="disease" post="2019 (COVIDâ€�19) outbreak: lessons from Taiwanâ€™s severe acute respiratory"/>
  <result pre="the coronavirus disease 2019 (COVIDâ€�19) outbreak: lessons from Taiwanâ€™s severe" exact="acute" post="respiratory syndrome response.Clin Infect Dis. 2020. 116ZhouF, YuT, DuR,"/>
  <result pre="coronavirus disease 2019 (COVIDâ€�19) outbreak: lessons from Taiwanâ€™s severe acute" exact="respiratory" post="syndrome response.Clin Infect Dis. 2020. 116ZhouF, YuT, DuR, et"/>
  <result pre="disease 2019 (COVIDâ€�19) outbreak: lessons from Taiwanâ€™s severe acute respiratory" exact="syndrome" post="response.Clin Infect Dis. 2020. 116ZhouF, YuT, DuR, et al."/>
  <result pre="et al. Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVIDâ€�19 in Wuhan, China: a retrospective cohort"/>
  <result pre="al. Contact and selfâ€�contact patterns of healthcare workers: implications for" exact="infection" post="prevention and control. Clin Infect Dis. 2019;69(Supplement_3):S178â€&quot;S184.31517975 118KuenzigME, RezaieA,"/>
  <result pre="study. Aliment Pharmacol Ther. 2002;16(6):1109â€&quot;1116.12030952 120FeaganBG, BhayatF, KhalidM, et al." exact="Respiratory" post="tract infections in patients with inflammatory bowel disease: safety"/>
  <result pre="Pharmacol Ther. 2002;16(6):1109â€&quot;1116.12030952 120FeaganBG, BhayatF, KhalidM, et al. Respiratory tract" exact="infections" post="in patients with inflammatory bowel disease: safety analyses from"/>
  <result pre="KhalidM, et al. Respiratory tract infections in patients with inflammatory" exact="bowel" post="disease: safety analyses from vedolizumab clinical trials. J Crohns"/>
  <result pre="et al. Longâ€�term safety of tofacitinib for the treatment of" exact="rheumatoid arthritis" post="up to 8.5 years: integrated analysis of data from"/>
  <result pre="al. Longâ€�term safety of tofacitinib for the treatment of rheumatoid" exact="arthritis" post="up to 8.5 years: integrated analysis of data from"/>
  <result pre="BodegravenAA. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of" exact="inflammatory bowel disease." post="Clin Pharmacokinet. 2018;57:1075â€&quot;1106.29512050 125GisbertJP, NinoP, CaraC, RodrigoL. Comparative effectiveness"/>
  <result pre="Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of inflammatory" exact="bowel" post="disease. Clin Pharmacokinet. 2018;57:1075â€&quot;1106.29512050 125GisbertJP, NinoP, CaraC, RodrigoL. Comparative"/>
  <result pre="2018;57:1075â€&quot;1106.29512050 125GisbertJP, NinoP, CaraC, RodrigoL. Comparative effectiveness of azathioprine in" exact="Crohn's disease" post="and ulcerative colitis: prospective, longâ€�term, followâ€�up study of 394"/>
  <result pre="125GisbertJP, NinoP, CaraC, RodrigoL. Comparative effectiveness of azathioprine in Crohn's" exact="disease" post="and ulcerative colitis: prospective, longâ€�term, followâ€�up study of 394"/>
  <result pre="and immune reconstitution following discontinuation of thiopurine analogues: implications for" exact="drug withdrawal" post="strategies. J Crohns Colitis. 2018;12:1410â€&quot;1417.30169593 127Vande CasteeleN, BaertF, BianS,"/>
  <result pre="Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat" exact="rheumatoid arthritis." post="Clin Pharmacokinet. 2015;54:1107â€&quot;1123.26123705 129KlotzU, TemlA, SchwabM. Clinical pharmacokinetics and"/>
  <result pre="Pharmacokinet. 2007;48:645â€&quot;660. 130TernantD, AubourgA, Magdelaineâ€�BeuzelinC, et al. Infliximab pharmacokinetics in" exact="inflammatory bowel disease" post="patients. Ther Drug Monit. 2008;30:523â€&quot;529.18641542 131HemperlyA, VandeCN. Clinical pharmacokinetics"/>
  <result pre="2007;48:645â€&quot;660. 130TernantD, AubourgA, Magdelaineâ€�BeuzelinC, et al. Infliximab pharmacokinetics in inflammatory" exact="bowel" post="disease patients. Ther Drug Monit. 2008;30:523â€&quot;529.18641542 131HemperlyA, VandeCN. Clinical"/>
  <result pre="130TernantD, AubourgA, Magdelaineâ€�BeuzelinC, et al. Infliximab pharmacokinetics in inflammatory bowel" exact="disease" post="patients. Ther Drug Monit. 2008;30:523â€&quot;529.18641542 131HemperlyA, VandeCN. Clinical pharmacokinetics"/>
  <result pre="Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of" exact="inflammatory bowel disease." post="Clin Pharmacokinet. 2018;57:929â€&quot;942.29330783 132TianH, CronsteinBN. Understanding the mechanisms of"/>
  <result pre="pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory" exact="bowel" post="disease. Clin Pharmacokinet. 2018;57:929â€&quot;942.29330783 132TianH, CronsteinBN. Understanding the mechanisms"/>
  <result pre="mechanisms of action of methotrexate: implications for the treatment of" exact="rheumatoid arthritis." post="Bull NYU Hosp Jt Dis. 2007;65:168â€&quot;173.17922664 133BestBM, CapparelliEV, DiepH,"/>
  <result pre="Review article: the pharmacokinetics and pharmacodynamics of drugs used in" exact="inflammatory bowel disease" post="treatment. Eur J Clin Pharmacol. 2015;71:773â€&quot;799.26008212"/>
  <result pre="article: the pharmacokinetics and pharmacodynamics of drugs used in inflammatory" exact="bowel" post="disease treatment. Eur J Clin Pharmacol. 2015;71:773â€&quot;799.26008212"/>
  <result pre="the pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel" exact="disease" post="treatment. Eur J Clin Pharmacol. 2015;71:773â€&quot;799.26008212"/>
 </snippets>
</snippetsTree>
